Figure 4. IFN-γ ELISPOT responses induced by a prime with the individual rBCG-HIV vaccines or a mix of the rBCG-HIV vaccines and rMVA boost.

Groups of mice were primed with either the individual rBCGpan-Gag, rBCGpan-RT or rBCGpan-gp120 vaccines (10⁷ cfu) or a rBCG vaccine mix (3×10⁷ cfu) prepared by mixing 10⁷ cfu of the individual rBCGpan-Gag, rBCGpan-RT and rBCGpan-gp120 vaccines. Groups of mice vaccinated with the rBCGpan-Control vaccine (10⁷ cfu to act as control for the individual vaccine vaccinations or 3×10⁷ cfu to act as control for the mix of the individual vaccine vaccinations) served as controls. All groups of mice were then boosted with MVA (10⁴ pfu) on day 28. On day 40 spleens were harvested and splenocytes pooled from 5 mice per group were used in an IFN-γ ELISPOT (A) or IL-2 ELISPOT (B) assay with Gag, RT, Env and peptide H CD8⁺ T cell and CD4⁺ T cell peptides. Bars are the average and standard deviation of the average IFN-γ ELISPOT (A) or IL-2 ELISPOT responses for the indicated individual peptides for 3 separate experiments. Statistical significance (Student's t-test for means of unpaired data) of the mean IFN-γ ELISPOT or IL-2 ELISPOT responses for the individual peptides compared to that for the control is indicated.